Clinical data and real-world results support the long-term efficacy of Biogen’s medications for multiple sclerosis (MS), according to scientific presentations being released by the company. Specifically, findings support the ... Read more
Research that points to a potential blood biomarker of multiple sclerosis (MS) severity, relates cognitive difficulties to patients’ employment and other measures of socioeconomic status, and one-year results of an ongoing ... Read more
Personalized medicine is the future of multiple sclerosis treatment, and research now taking place to collect and analyze data and pinpoint biomarkers will help make possible approaches that — ... Read more
In its work on multiple sclerosis (MS), Biogen has adopted a comprehensive approach that ranges from drug development to the exploration of real-world data and digital markers of disease.
The company ... Read more